Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03241446
Recruitment Status : Withdrawn (This study was combined with another trial that was on-going.)
First Posted : August 7, 2017
Last Update Posted : October 9, 2018
Sponsor:
Information provided by (Responsible Party):
Navidea Biopharmaceuticals

Brief Summary:
A prospective, open-label, single center, study to evaluate pharmacokinetics and dosimetry of intravenously injected Tc 99m tilmanocept at three mass doses (50 µg, 200 µg, and 400 µg) radiolabeled with 10 millicuries (mCi) Tc 99m.

Condition or disease Intervention/treatment Phase
Arthritis, Rheumatoid Drug: Tilmanocept Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: A Phase I, Open-Label Study to Investigate the Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis
Estimated Study Start Date : September 2017
Estimated Primary Completion Date : January 2018
Estimated Study Completion Date : March 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 50 ug Tilmanocept
Single dose of 50 ug tilmanocept radiolabeled with 10 mCi technetium Tc99m
Drug: Tilmanocept
Intravenously administered Technetium Tc 99m tilmanocept

Experimental: 200 ug Tilmanocept
Single dose of 200 ug tilmanocept radiolabeled with 10 mCi technetium Tc99m
Drug: Tilmanocept
Intravenously administered Technetium Tc 99m tilmanocept

Experimental: 400 ug Tilmanocept
Single dose of 400 ug tilmanocept radiolabeled with 10 mCi technetium Tc99m
Drug: Tilmanocept
Intravenously administered Technetium Tc 99m tilmanocept




Primary Outcome Measures :
  1. Maximum Plasma concentration (Cmax) of Technetium Tc 99m Tilmanocept [ Time Frame: 1 Days ]
    Maximum Plasma concentration (Cmax) of Technetium Tc 99m Tilmanocept

  2. Plasma Area Under the Curve (AUC) of Technetium Tc 99m Tilmanocept [ Time Frame: 2 Days ]
    Plasma Area Under the Curve (AUC) of Technetium Tc 99m Tilmanocept

  3. Systemic Clearance (CLs) of Technetium Tc 99m Tilmanocept [ Time Frame: 3 Days ]
    Systemic Clearance (CLs) of Technetium Tc 99m Tilmanocept

  4. Renal Clearance (CLr) of Technetium Tc 99m Tilmanocept [ Time Frame: 2 days ]
    Renal Clearance (CLr) of Technetium Tc 99m Tilmanocept

  5. Terminal Elimination Half-Life (T1/2) of Technetium Tc 99m Tilmanocept [ Time Frame: 3 days ]
    Terminal Elimination Half-Life (T1/2) of Technetium Tc 99m Tilmanocept

  6. Clinical Dosimetry of Technetium Tc 99m Tilmanocept [ Time Frame: 3 days ]
    Clinical Dosimetry of Technetium Tc 99m Tilmanocept


Secondary Outcome Measures :
  1. Incidence of Adverse Events [ Time Frame: 7 Days ]
    Incidence of Adverse Events



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. The subject has provided written informed consent with HIPAA (Health Information Portability and Accountability Act) authorization before the initiation of any study-related procedures.
  2. The subject is 30 - 65 years of age at the time of consent.
  3. Has a negative urine drug screening for illicit or unprescribed drugs suggestive of drug abuse.
  4. Subjects will have a BMI of 18 to 34 kg/m2, inclusive, at Screening
  5. The subject has active RA as determined by the Clinical Disease Activity Index score of ≥ 10 and have ≥ 2 swollen joints.
  6. If the subject is receiving methotrexate, they have been at a stable dose for > 4 weeks prior to the Day 1 visit.
  7. If the subject is receiving biologic therapy or other DMARDs, they have been at a stable dose > 8 weeks prior to the Day 1 visit.
  8. If the subject is receiving NSAIDS or oral corticosteroids, the dose has been at a stable dose for > 4 weeks prior to the Day 1 visit. The corticosteroid dose should be ≤ 10mg/day of prednisone or an equivalent steroid dose.
  9. Aside from being diagnosed with rheumatoid arthritis, subjects must be in good health, as determined by medical history, physical examination, vital sign assessment, 12 lead electrocardiogram (ECG) and clinical laboratory evaluations.

Exclusion Criteria:

  1. The subject is pregnant or lactating.
  2. The subject has a significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder (as determined by the Investigator)
  3. The subject has a history of significant hypersensitivity, intolerance, or allergy to dextran or modified forms of dextran; unless approved by the Investigator
  4. The subject has a history or presence of an abnormal ECG, which, in the Investigator's opinion, is clinically significant
  5. The subject has participated in a radiolabeled investigational study drug trial within 3 months prior to Day 1
  6. The subject has exceeded yearly radioactive dose of 30 millisieverts (mSv)
  7. The subject has a history of drug abuse or alcohol within 2 years before dose administration, or positive drug or alcohol test at screening.
  8. The subject has used tobacco- or nicotine-containing products (including but not limited to cigarettes, e-cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months prior to Day 1, or positive cotinine screen
  9. The subjects uses any prescription medications within 14 days prior to Day 1, except as allowed by the inclusion criteria or as deemed acceptable by the Investigator;
  10. The subject uses any over-the-counter, non-prescription preparations (including vitamins, minerals, and phytotherapeutic/ herbal/plant-derived preparations) within 7 days prior to Day 1, unless deemed acceptable by the Investigator;
  11. The subject has poor peripheral venous access;
  12. The subject has donated blood within 30 days prior to Day 1, or plasma within 2 weeks prior to Day 1
  13. The subject has received blood products within 2 months prior to Day 1;
  14. The subject has any acute or chronic condition that, in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in this clinical study.
  15. The subject has received any radiopharmaceutical within 7 days prior to the administration of Tc 99m tilmanocept.
Layout table for additonal information
Responsible Party: Navidea Biopharmaceuticals
ClinicalTrials.gov Identifier: NCT03241446    
Other Study ID Numbers: NAV3-26
First Posted: August 7, 2017    Key Record Dates
Last Update Posted: October 9, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases